A 26-person sleep-peptide pilot reports signals—not a verdict

What happened

A randomized, placebo-controlled pilot tested a rice-protein hydrolysate marketed as PeptiSleep in 26 adults with sleep impairment over 56 days. The ingredient was identified using an in-silico peptide-discovery approach, and the study combined questionnaires with exploratory Oura wearable measurements.

What the study found

The active group scored higher across Leeds Sleep Evaluation Questionnaire categories, with nominal p-values at or near 0.05 for getting to sleep and perceived sleep quality. Total mood disturbance also showed a nominal difference. Sleep diaries and questionnaires covering stress, anxiety, sleepiness and insomnia did not show significant group differences.

Evidence check

The authors describe the study as small, single-blind and exploratory. Secondary outcomes were not adjusted for multiple comparisons, increasing the chance of apparently positive findings. Wearable-derived differences were exploratory, and a 26-person pilot cannot establish reliable efficacy, safety in broader populations or durability.

Why it matters

Computational ingredient discovery is moving into consumer wellness faster than traditional drug development. That makes transparent trial design and replication more—not less—important. The available signal supports a larger preregistered study, not a clinical claim that the product treats insomnia.